Egetis Therapeutics
4.76 SEK
+1.06 %
Less than 1K followers
EGTX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+1.06 %
-23.84 %
-5.56 %
+17.53 %
-32.00 %
-11.36 %
+16.10 %
-21.75 %
-65.60 %
Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.
Read moreMarket cap
2.02B SEK
Turnover
5.59M SEK
Revenue
46.1M
EBIT %
-714.53 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26/2
2026
Annual report '25
29/4
2026
Interim report Q1'26
6/5
2026
General meeting '26
All
Webcasts
Press releases
3rd party
ShowingAll content types
New publication highlights meaningful clinical benefits of Emcitate® (tiratricol) in treating Resistance to Thyroid Hormone Beta
Medlemmar av Egetis Ledningsgrupp förvärvar aktier i Egetis
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
